Adrenal steroid hormone concentrations in dogs with hair cycle arrest (Alopecia X) before and during treatment with melatonin and mitotane.
The purpose of the study was to evaluate intermediate adrenal steroid hormones (ISH) in neutered dogs with hair cycle arrest (Alopecia X) during treatment with melatonin, and to see if hair re-growth is associated with sex hormone concentrations within the normal ranges. Twenty-nine neutered, euthyroid, and normo-cortisolemic dogs were enrolled in the study (23 Pomeranians, three keeshonds, two miniature poodles, and one Siberian husky). Coat assessment and an ACTH stimulation test were performed pre-treatment and approximately every 4 months for a year post treatment. Melatonin was administered initially at 3-6 mg, every 12 h. Based on clinical progression, each dog was continued on the current dose of melatonin, given an increased dose of melatonin or changed to mitotane. Partial to complete hair re-growth occurred in 14/23 Pomeranians, and partial re-growth in 3/3 keeshond and 1/2 poodle dogs. A Siberian husky dog failed to re-grow hair. Fifteen dogs had partial hair re-growth at the first re-evaluation. Melatonin dosage was increased in eight dogs but only one had improved hair re-growth. On mitotane treatment, partial to complete hair re-growth was seen in 4/6 dogs and no re-growth in 2/6 dogs. No significant decrease in sex hormone concentrations were seen during melatonin or mitotane treatment. Concentrations of ISH in dogs with hair re-growth did not differ significantly from pre-treatment values. At the completion of the study, androstenedione, progesterone and 17-hydroxyprogesterone were still above reference ranges in 21, 64 and 36%, respectively, of dogs with partial to complete hair re-growth. In conclusion, 62% of dogs had partial to complete hair re-growth. However, not all dogs with hair re-growth had concentrations of ISH within the normal range.
Frank
Linda A
LA
Department of Small animal Clinical Sciences, University of Tennessee, C247 Veterinary Teaching Hospital, Knoxville, TN 37996-4544, USA. lfrank@utk.edu
Hnilica
Keith A
KA
Oliver
Jack W
JW
D000284:Administration, Oral; D000305:Adrenal Cortex Hormones / Q000097:blood*; D000324:Adrenocorticotropic Hormone; D000505:Alopecia / Q000188:drug therapy / Q000662:veterinary*; D000735:Androstenedione / Q000097:blood; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D004283:Dog Diseases / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D004958:Estradiol / Q000097:blood; D005260:Female; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D008550:Melatonin / Q000008:administration & dosage / Q000627:therapeutic use*; D008939:Mitotane / Q000008:administration & dosage / Q000627:therapeutic use*; D011374:Progesterone / Q000097:blood; D013577:Syndrome; D013739:Testosterone / Q000097:blood
D000305:Adrenal Cortex Hormones; D018931:Antineoplastic Agents, Hormonal; D013739:Testosterone; D000735:Androstenedione; D011374:Progesterone; D004958:Estradiol; D008939:Mitotane; D000324:Adrenocorticotropic Hormone; D008550:Melatonin; D006854:Hydrocortisone